Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,757 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06475131RecruitingPhase 1
Study of BL-B16D1 for advanced solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06179160RecruitingPhase 1
Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Gilbert, ArizonaAges 18 years+ - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06154291RecruitingPhase 1/Phase 2
XON7 for advanced or metastatic solid tumors
This trial tests an experimental drug called XON7 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if XON7 is safe and effective.
AnderlechtAges 18 years+ - NCT06046742RecruitingPhase 1
IV M1-c6v1 for advanced solid tumors
This trial tests an experimental drug called M1-c6v1 given through an IV for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective.
Kashiwa-shi, ChibaAges 18 years+ - NCT05857332RecruitingPhase 1
Testing a new drug for CLDN18.2-positive solid tumors
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05470348RecruitingPhase 1
Test drug BL-B01D1 for advanced breast and other solid cancers
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Guangzhou, GuangdongAges 18–75 - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT05004116RecruitingPhase 1/Phase 2
Repotrectinib plus chemotherapy for relapsed solid tumors in youth
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
New York, New YorkAges 1–25 - NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04471987RecruitingPhase 1
IL-12 drug for metastatic cancer after checkpoint therapy
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Hamburg, Free and Hanseatic City of HamburgAges 18–80 - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Duarte, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,757 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.